1 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCCHead and Neck Neoplasms, Neoplasms by Site, head and neck cancer, neoplasmRecruitingPhase 22025-03-14NCT06876844